Bio-Techne completes acquisition of Exosome Diagnostics for up to $575 million

Bio-Techne Corporation completed its acquisition of Exosome Diagnostics, Inc. with an upfront payment of $250 million and up to $325 million in additional milestone payments through 2022.

“Bio-Techne Corporation today announced it has completed its acquisition of Exosome Diagnostics, Inc.”prnewswire.com

• 1 source
• prnewswire.comBio-Techne Corporation Completed Its Acquisition of Exosome Diagnostics, Inc.Bio-Techne CorporationAug 1, 2018

Summarized from public sources; check the original articles before acting on it.